DWA
INZY

Dorsey Wright & Associates’s Inozyme Pharma INZY Stock Holding History

Dorsey Wright & Associates’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,445
Closed -$19.2K – 304
2023
Q2 		$19.2K Buy
+3,445
New +$20.4K 0.01% 268

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dorsey Wright & Associates's INZY Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of Inozyme Pharma (INZY) in Q3 2023, closing a stake of 3,445 shares — an estimated $19.2K sold.

Dorsey Wright & Associates first reported a position in INZY in Q2 2023 and held it in 1 quarter. The position peaked at $19.2K in Q2 2023. 77 funds tracked by Wall St. Rank hold INZY as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining Inozyme Pharma position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 3,445 Inozyme Pharma shares in Q3 2023, an estimated $19.2K.
  • Dorsey Wright & Associates first reported a position in Inozyme Pharma in Q2 2023 and held it in 1 quarter.
  • Dorsey Wright & Associates's Inozyme Pharma position peaked at $19.2K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.